These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18194079)

  • 1. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients.
    Beran J
    Expert Opin Biol Ther; 2008 Feb; 8(2):235-47. PubMed ID: 18194079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
    Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
    Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New hepatitis B vaccine formulated with an improved adjuvant system.
    Kundi M
    Expert Rev Vaccines; 2007 Apr; 6(2):133-40. PubMed ID: 17408363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed.
    Prescrire Int; 2008 Dec; 17(98):234-6. PubMed ID: 19422145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population.
    Fabrizi F; Martin P; Messa P
    Int J Artif Organs; 2015 Dec; 38(12):625-31. PubMed ID: 26821784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients.
    Kapoor D; Aggarwal SR; Singh NP; Thakur V; Sarin SK
    J Viral Hepat; 1999 Sep; 6(5):405-9. PubMed ID: 10607257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
    Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
    Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population.
    Fabrizi F; Cerutti R; Nardelli L; Tripodi F; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):49-56. PubMed ID: 31327620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients.
    Kong NC; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; Calbo-Torrecillas F; López de Novales E; Srinivasa K; Stoffel M; Hoet B
    Kidney Int; 2008 Apr; 73(7):856-62. PubMed ID: 18160963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients.
    Fabrizi F; Dixit V; Messa P; Martin P
    Aliment Pharmacol Ther; 2010 Sep; 32(6):756-62. PubMed ID: 20662784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.
    Surquin M; Tielemans CL; Kulcsár I; Ryba M; Vörös P; Mat O; Treille S; Dhaene M; Stolear JC; Kuriyakose SO; Leyssen MX; Houard SA
    Kidney Int; 2010 Feb; 77(3):247-55. PubMed ID: 19940840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.
    Alavian SM; Tabatabaei SV
    Clin Ther; 2010 Jan; 32(1):1-10. PubMed ID: 20171406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and immunization costs of adjuvanted versus non-adjuvanted hepatitis B vaccine in chronic kidney disease patients.
    Vilajeliu A; Sequera VG; García-Basteiro AL; Sicuri E; Aldea M; Velasco C; Bayas JM
    Hum Vaccin Immunother; 2016 Sep; 12(9):2317-21. PubMed ID: 27105182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff.
    Tele SA; Martins RM; Lopes CL; dos Santos Carneiro MA; Souza KP; Yoshida CF
    Eur J Epidemiol; 2001; 17(2):145-9. PubMed ID: 11599688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
    Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
    Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B vaccination in haemodialysis patients: an underestimated problem. Factors influencing immune responses in ten years of observation in an Italian haemodialysis centre and literature review.
    Cordova E; Miglia I; Festuccia F; Sarlo MG; Scornavacca G; Punzo G; Menè P; Fofi C
    Ann Ig; 2017; 29(1):27-37. PubMed ID: 28067935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines.
    Grzegorzewska AE
    Expert Rev Vaccines; 2014 Nov; 13(11):1317-26. PubMed ID: 25148051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.